Private company

Kaleido Biosciences, Inc.

American biological products company, incorporated in Delaware.

Last updated Oct 18, 2026.

Overview

IndustryBiological Products, (No Diagnostic Substances)
HeadquartersDE
Incorporated inDE²
Business address18 Crosby Drive, Bedford, Ma 01730²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-7940.9%Operating margin³

-8178.3%Net margin³

13.2%Revenue growth, 2021³

-851.2%Return on equity³

0.52×Debt to equity³

-$78.2MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2021

Research and development

Research and development96¢$67.8M
Interest4¢$2.8M

Out of $1.1M in revenue.³ The company lost money this year.

Financial statements

Revenue³$1.1M in 2021+13% since 2020

Operating income⁴⁵³-$87.7M in 2021+44% since 2018

Net income⁴⁵³-$90.3M in 2021+46% since 2018

Fiscal year	2018	2019	2020	2021
Revenue			$975.0K³	$1.1M³
Research and development	$42.1M⁴	$64.2M⁵	$56.0M³	$67.8M³
Operating income	-$60.7M⁴	-$86.7M⁵	-$78.9M³	-$87.7M³
Interest	$1.0M⁴	$977.0K⁵	$2.8M³	$2.8M³
Income tax		$0⁴	$0⁵
Net income	-$61.7M⁴	-$86.3M⁵	-$81.6M³	-$90.3M³

Total assets⁴⁵³$50.1M in 2021−41% since 2018

Total liabilities⁴⁵³$39.5M in 2021+39% since 2018

Shareholders’ equity⁴⁵³$10.6M in 2021

Cash⁴⁵³$38.5M in 2021+34% since 2017

Long-term debt⁴⁵³$5.5M in 2021−63% since 2018

Fiscal year	2017	2018	2019	2020	2021
Cash	$28.7M⁴	$76.1M⁴	$71.2M⁵	$46.2M³	$38.5M³
Current assets		$76.2M⁴	$73.3M⁵	$48.7M³	$42.3M³
Total assets		$85.3M⁴	$82.3M⁵	$59.3M³	$50.1M³
Current liabilities		$11.3M⁴	$10.4M⁵	$16.7M³	$29.7M³
Long-term debt		$14.8M⁴	$20.4M⁵	$18.4M³	$5.5M³
Total liabilities		$28.3M⁴	$33.4M⁵	$38.8M³	$39.5M³
Shareholders’ equity	-$43.7M⁴	-$96.2M⁵	$48.9M³	$20.5M³	$10.6M³
Shares outstanding		5.8M shares⁴	30.1M shares⁵	36.0M shares³	42.6M shares³

Cash from operations⁴⁵³-$77.1M in 2021+66% since 2018

Capital spending⁴⁵³$1.1M in 2021−62% since 2018

Free cash flow⁴⁵³-$78.2M in 2021+59% since 2018

Fiscal year	2018	2019	2020	2021
Cash from operations	-$46.3M⁴	-$75.8M⁵	-$61.5M³	-$77.1M³
Capital spending	$3.0M⁴	$3.6M⁵	$4.0M³	$1.1M³
Free cash flow	-$49.3M	-$79.4M	-$65.5M	-$78.2M

Compare Kaleido Biosciences, Inc. with another company

Leadership

Who has led Kaleido Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

20202025

Chief executive officerDaniel L. Menichella Oct 19, 2020 to Jan 18, 2022⁶
ChairMichael W. Bonney Feb 27, 2019 to Mar 4, 2019⁷
Chief financial officerWilliam E. Duke Nov 22, 2019 to Jan 18, 2022⁸
Chief operating officerJerald Korn Jan 18, 2022 to Mar 2, 2022⁹

Board members and other officers (19)

Chief Scientific OfficerHylckama Vlieg Johan Van May 13, 2021 to Mar 2, 2022¹⁰
Chief Medical OfficerAlison S. Long Dec 16, 2021 to Jan 18, 2022¹¹
OfficerAlison Francis Lawton Feb 27, 2019 to Apr 17, 2020¹²
OfficerJoshua T. Brumm Feb 27, 2019 to Mar 4, 2019¹³
OfficerKatharine Knobil Feb 27, 2019 to Oct 19, 2020¹⁴
Principal Accounting OfficerRichard William Scalzo Oct 15, 2019 to Oct 15, 2019¹⁵
Board memberAnne Prener Apr 3, 2020 to Jul 1, 2021¹⁶
Board memberMichael W. Bonney Jul 1, 2020 to Jul 1, 2021¹⁷
Board memberDaniel L. Menichella Oct 19, 2020 to Jan 18, 2022⁶
Board memberAlison Francis Lawton Feb 27, 2019 to Apr 17, 2020¹²
Board memberAnthony Quinn Feb 27, 2019 to Jul 1, 2021¹⁸
Board memberBonnie L. Bassler Feb 27, 2019 to Jul 1, 2021¹⁹
Board memberGrady Burnett Feb 27, 2019 to Jul 1, 2021²⁰
Board memberJohn Sculley Feb 27, 2019 to Feb 27, 2019²¹
Board memberMaltzahn Geoffrey Von Feb 27, 2019 to Jul 1, 2021²²
Board memberNoubar Afeyan Feb 27, 2019 to Mar 6, 2019²³
Board memberKyriazi Theo Melas Jul 19, 2019 to Jul 1, 2021²⁴
Board memberJean K. Mixer Oct 2, 2019 to Jul 1, 2021²⁵
General counselJerald Korn Jul 23, 2019 to Mar 2, 2022²⁶

Timeline

Oct 19, 2020New chief executive Daniel L. Menichella becomes CEO⁶

Filings

27 filings to the SEC since October 2021: 1 annual reports, 1 quarterly reports, 6 major events, 9 insider forms, 2 large holders, 8 other. The latest 20:

The 27 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 2 such filings since October 2021:

May 10, 2022SC 13G/A
Feb 9, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARKaleido Biosciences, Inc. filings on SEC EDGAR
2
SEC EDGARKaleido Biosciences, Inc. filings on SEC EDGAR
3
SEC EDGARKaleido Biosciences, Inc. 10-K for fiscal 2021
4
SEC EDGARKaleido Biosciences, Inc. 10-K for fiscal 2018
5
SEC EDGARKaleido Biosciences, Inc. 10-K for fiscal 2019
6
SEC EDGARDaniel L. Menichella, Chief executive officer
7
SEC EDGARMichael W. Bonney, Chair
8
SEC EDGARWilliam E. Duke, Chief financial officer
9
SEC EDGARJerald Korn, Chief operating officer
10
SEC EDGARHylckama Vlieg Johan Van, Chief Scientific Officer
11
SEC EDGARAlison S. Long, Chief Medical Officer
12
SEC EDGARAlison Francis Lawton, Officer
13
SEC EDGARJoshua T. Brumm, Officer
14
SEC EDGARKatharine Knobil, Officer
15
SEC EDGARRichard William Scalzo, Principal Accounting Officer
16
SEC EDGARAnne Prener, Board member
17
SEC EDGARMichael W. Bonney, Board member
18
SEC EDGARAnthony Quinn, Board member
19
SEC EDGARBonnie L. Bassler, Board member
20
SEC EDGARGrady Burnett, Board member
21
SEC EDGARJohn Sculley, Board member
22
SEC EDGARMaltzahn Geoffrey Von, Board member
23
SEC EDGARNoubar Afeyan, Board member
24
SEC EDGARKyriazi Theo Melas, Board member
25
SEC EDGARJean K. Mixer, Board member
26
SEC EDGARJerald Korn, General counsel